Cargando…
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
Autores principales: | Giustina, A., Ambrosio, M. R., Beck Peccoz, P., Bogazzi, F., Cannavo’, S., De Marinis, L., De Menis, E., Grottoli, S., Pivonello, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182612/ https://www.ncbi.nlm.nih.gov/pubmed/25245336 http://dx.doi.org/10.1007/s40618-014-0146-x |
Ejemplares similares
-
Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017) -
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022) -
COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology
por: Puig-Domingo, M., et al.
Publicado: (2021) -
Italian guidelines for the treatment of type 2 diabetes
por: Mannucci, Edoardo, et al.
Publicado: (2022) -
2023 update on Italian guidelines for the treatment of type 2 diabetes
por: Mannucci, Edoardo, et al.
Publicado: (2023)